On October 19, 2021, MicroTech Medical (Hangzhou) Co., Ltd. ("MicroTech Medical") completed the initial public offering of H shares and has been listed on the main board of the Hong Kong Stock Exchange (the code: 2235.HK). As the issuer's China legal advisor, Llinks has provided full legal services for Weitai Medical's issuance and listing.
Founded in 2011, Weitai Medical focuses on the field of diabetes monitoring and treatment devices, and is committed to optimizing diabetes management models on a global scale through leading technological products and service concepts to help diabetic patients have a healthier and better life. Equil (a patch insulin pump) , one of the core product of Weitai Medical, is the world's only patch insulin pump system that is simultaneously marketed in China and the EU; AiDEX G7 is one of the few commercialized "14 days, calibration-free, real-time" in the world Dynamic blood glucose monitoring system. Over the past ten years, Weitai Medical has been adhering to the corporate mission of " leading healthy life through technology innovation " to bring real life-changing technology products to the majority of diabetic patients.
